Acadian Asset Management LLC lifted its position in Haemonetics Corporation (NYSE:HAE) by 100.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 524,768 shares of the medical instruments supplier’s stock after acquiring an additional 263,432 shares during the quarter. Acadian Asset Management LLC owned approximately 0.99% of Haemonetics worth $30,479,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of HAE. Riverhead Capital Management LLC grew its stake in shares of Haemonetics by 79.3% in the 2nd quarter. Riverhead Capital Management LLC now owns 3,407 shares of the medical instruments supplier’s stock worth $135,000 after acquiring an additional 1,507 shares in the last quarter. Shelton Capital Management bought a new stake in shares of Haemonetics in the 2nd quarter worth $204,000. Cubist Systematic Strategies LLC bought a new stake in shares of Haemonetics in the 2nd quarter worth $260,000. Amalgamated Bank grew its stake in shares of Haemonetics by 5.7% in the 2nd quarter. Amalgamated Bank now owns 7,322 shares of the medical instruments supplier’s stock worth $289,000 after acquiring an additional 392 shares in the last quarter. Finally, First Allied Advisory Services Inc. bought a new stake in shares of Haemonetics in the 2nd quarter worth $316,000.
Haemonetics Corporation (HAE) opened at $64.39 on Friday. The firm has a market cap of $3,437.94, a PE ratio of 804.98, a P/E/G ratio of 4.91 and a beta of 0.99. The company has a current ratio of 2.17, a quick ratio of 1.51 and a debt-to-equity ratio of 0.22. Haemonetics Corporation has a 1 year low of $36.44 and a 1 year high of $65.25.
Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.07. The company had revenue of $225.40 million during the quarter, compared to analyst estimates of $219.12 million. Haemonetics had a net margin of 0.50% and a return on equity of 11.16%. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.38 earnings per share. equities analysts forecast that Haemonetics Corporation will post 1.69 EPS for the current year.
Several research firms have recently issued reports on HAE. Zacks Investment Research lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 10th. Jefferies Group upped their target price on shares of Haemonetics from $18.00 to $75.00 and gave the stock a “buy” rating in a research note on Monday, January 8th. Raymond James Financial upgraded shares of Haemonetics from an “underperform” rating to a “market perform” rating in a research note on Tuesday, January 2nd. Morgan Stanley upgraded shares of Haemonetics from an “equal weight” rating to an “overweight” rating and set a $51.00 price target for the company in a research report on Tuesday, January 2nd. Finally, Craig Hallum restated a “hold” rating and set a $50.00 price target (up previously from $40.00) on shares of Haemonetics in a research report on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $58.83.
In other Haemonetics news, CAO Dan Goldstein sold 4,691 shares of the stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $54.93, for a total transaction of $257,676.63. Following the completion of the transaction, the chief accounting officer now owns 3,747 shares in the company, valued at $205,822.71. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark W. Kroll sold 7,118 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $63.00, for a total transaction of $448,434.00. Following the transaction, the director now owns 33,881 shares of the company’s stock, valued at approximately $2,134,503. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 54,486 shares of company stock valued at $3,050,827. 1.20% of the stock is owned by company insiders.
Haemonetics Company Profile
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.